OrthoEvidence Trial Assessing Japanese Knowledge Updates (OTAKU)

July 30, 2022 updated by: McMaster University

OrthoEvidence Trial Assessing Japanese Knowledge Updates : Trial of Knowledge Translation Among Japanese Surgeons

The purpose of this randomized controlled trial is to clarify whether providing translated evidence summary (Advanced Clinical Evidence (ACE) reports from OrthoEvidence) will increase the access to the summary compared to providing the original version of evidence summary among Japanese orthopaedic surgeons

Study Overview

Detailed Description

The investigators will conduct the survey regarding baseline characteristics, barriers and familiality to evidence-based medicine by online. After the survey, the participants will be randomly assigned to receive either the original version of ACE reports or Japanese version of ACE reports. The pdf of each ACE report will be provided to the participants through an email link. Twenty reports will be sent over 4 weeks period. After that, the investigators will conduct another survey regarding the reports.

Study Type

Interventional

Enrollment (Actual)

105

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Hamilton, Ontario, Canada, L8S 4E8
        • McMaster University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Member of Japanese Society for Fracture Repair (JSFR)
  2. Spend at least 20% of their time in clinical practice
  3. Non-native speaker of English
  4. Has regular access to internet
  5. Prefer to read Japanese-translated material, if there are both translated and English version of the same material.

Exclusion Criteria:

We will exclude surgeons who cannot provide informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Japanese group
Participants who will receive Japanese-translated version of evidence summaries
Participants will receive emails with the link to Japanese-translated version of evidence summaries.
Active Comparator: English group
Participants who will receive English version of evidence summaries
Participants will receive emails with the link to English version of evidence summaries.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of access to evidence summaries
Time Frame: Four weeks (28 days) after the commencement of the trial
Total number of access to evidence summaries
Four weeks (28 days) after the commencement of the trial

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-rated score of understanding the contents of the provided materials
Time Frame: Within four weeks after the end of intervention
Five-point Likert scale in understanding the contents of provided materials, evaluated by the participants (higher scores means better outcome)
Within four weeks after the end of intervention
Self-rated score in changing their practice based on the contents of the materials
Time Frame: Within four weeks after the end of intervention
Five-point Likert scale in changing their practice based on the contents of the materials evaluated by the participants (higher scores means better outcome)
Within four weeks after the end of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kim Madden, PhD, McMaster University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 8, 2022

Primary Completion (Actual)

July 1, 2022

Study Completion (Actual)

July 29, 2022

Study Registration Dates

First Submitted

January 31, 2022

First Submitted That Met QC Criteria

February 10, 2022

First Posted (Actual)

February 22, 2022

Study Record Updates

Last Update Posted (Actual)

August 2, 2022

Last Update Submitted That Met QC Criteria

July 30, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteer

Subscribe